

# Acute Lymphoblastic Leukemia

## Posters and Abstracts from San Diego

### Abbreviations

**AEs:** adverse events

**ALL:** acute lymphoblastic leukemia

**allo-SCT:** allogeneic stem-cell transplantation

**AST/ALT:** aspartate transaminase/alanine transaminase

**BCP:** B-cell precursor

**CR:** complete remission

**CRi:** CR with incomplete count recovery

**CRS:** cytokine release syndrome

**DFS:** disease-free survival

**ECOG PS:** Eastern Cooperative Oncology Group Performance Status

**EFS:** event-free survival

**HRQoL:** health-related quality of life

**Hyper-CVAD:** hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate/cytarabine every 21 days

**INO:** inotuzumab ozogamicin

**IT:** intrathecal

**IV:** intravenous

**MRD:** minimal/measurable residual disease

**Mini-hyper-CVD:** cyclophosphamide and dexamethasone at 50% dose reduction, no doxorubicin, methotrexate at 75% dose reduction, and cytarabine at  $0.5 \text{ g/m}^2 \times 4$  doses

**NR:** not reached

**ORR:** overall response rate

**OS:** overall survival

**Ph:** Philadelphia chromosome

**POMP:** 6-mercaptopurine, vincristine, methotrexate, and prednisone

**qPCR:** quantitative polymerase chain reaction

**R/R:** relapsed/refractory

**SOC:** standard of care

**TKI:** tyrosine kinase inhibitor

**ULN:** upper limit of normal

**VOD:** veno-occlusive disease